BioSpace News Archive

CareDx, Inc. announced that AlloSeq HCT was selected as the primary solution for chimerism monitoring of stem cell transplant patients by the French National Blood Service, Établissement Français du Sang.

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced positive results from a first-in-patients 12-week Phase 2 proof-of-concept trial of BT-11, a novel, orally administered, gut-restricted LANCL2 modulator in patients with mild to moderate ulcerative colitis (UC).

88,000 square foot state-of-the-art facility will support Oncorus’ advancing, multi-product pipeline of intratumorally and intravenously administered viral immunotherapies

Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discuss the company’s transformation and growth initiatives at the 39th Annual J.P. Morgan Healthcare Conference at 2:50 p.m. EST on January 11, 2021. Mr. Diaz will focus on key opportunities to fulfill the company’s mission of improving patient lives by unlocking the power of precision medicine and helping h

- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted anti-tumor activity, creating new opportunities with Lantern’s portfolio of DNA damage compounds - Lantern plans on evaluating and potentially launching additional programs with the ADC compounds and novel linker technologies in cancers where drug resistance is a key issue

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference. The conference is being conducted in a virtual format and the pres

-FDA sets PDUFA goal date of July 2, 2021- -If approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes-

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 , at 2:00 p.m EST. A live and archived webcast of the event will be available in the Investors section o

Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present at two upcoming virtual investor conferences: H.C. Wainwright Virtual BioConnect

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron’s President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 11 at 10:00 a.m. EST, in a virtual format. A live webcast of the presentation will be accessible under “Events and Presentations” in the Investors & M